NCT01523587 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 398
- group Id
- BG001
- value
- 397
- group Id
- BG002
- value
- 795
- units
- Participants
- groups
- description
- Patients administered 40 milligram (mg) film-coated tablet once daily orally for the first 28-day treatment course. Dose escalation to 50 mg once daily was allowed at the beginning of the second 28-day treatment course, if patients met specified safety and compliance criteria. Dose reduction to 40 mg/day (if applicable), 30 mg/day, or 20 mg/day, was required in the presence of known drug-related adverse events.
- id
- BG000
- title
- Afatinib
- description
- Patients administered 150 mg film-coated tablet once daily orally, with dose reduction to 100 mg/day or 50 mg/day in the presence of known drug-related adverse events.
- id
- BG001
- title
- Erlotinib
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.39
- value
- 64.9
- group Id
- BG001
- spread
- 8.98
- value
- 63.4
- group Id
- BG002
- spread
- 8.72
- value
- 64.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- Randomised set
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 63
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 129
- title
- Female
- measurements
- group Id
- BG000
- value
- 335
- group Id
- BG001
- value
- 331
- group Id
- BG002
- value
- 666
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Randomised set
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 97
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 191
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 15
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 288
- group Id
- BG001
- value
- 291
- group Id
- BG002
- value
- 579
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Unknown or Not Reported
- description
- Ethnicity was not captured in this trial.
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Randomised set
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Randomized Set (RS): All patients who were randomized, regardless of whether they received investigational treatment.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 398
- group Id
- BG001
- value
- 397
- group Id
- BG002
- value
- 795
- units
- Participants
- groups
- description
- Patients administered 40 milligram (mg) film-coated tablet once daily orally for the first 28-day treatment course. Dose escalation to 50 mg once daily was allowed at the beginning of the second 28-day treatment course, if patients met specified safety and compliance criteria. Dose reduction to 40 mg/day (if applicable), 30 mg/day, or 20 mg/day, was required in the presence of known drug-related adverse events.
- id
- BG000
- title
- Afatinib
- description
- Patients administered 150 mg film-coated tablet once daily orally, with dose reduction to 100 mg/day or 50 mg/day in the presence of known drug-related adverse events.
- id
- BG001
- title
- Erlotinib
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.39
- value
- 64.9
- group Id
- BG001
- spread
- 8.98
- value
- 63.4
- group Id
- BG002
- spread
- 8.72
- value
- 64.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- Randomised set
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 63
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 129
- title
- Female
- measurements
- group Id
- BG000
- value
- 335
- group Id
- BG001
- value
- 331
- group Id
- BG002
- value
- 666
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Randomised set
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 97
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 191
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 15
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 288
- group Id
- BG001
- value
- 291
- group Id
- BG002
- value
- 579
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Unknown or Not Reported
- description
- Ethnicity was not captured in this trial.
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Randomised set
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Randomized Set (RS): All patients who were randomized, regardless of whether they received investigational treatment.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle